This is decidedly good news for all the emerging immuno-oncology candidates -- Merck's plainly here included. Here's a bit from US News & World Report:
. . . .According to the Global Oncology Trend Report, released Tuesday by the IMS Institute for Healthcare Informatics, global spending on cancer medications rose 10.3 percent in 2014 to $100 billion, up from $75 billion in 2010.
"We've made huge progress from a scientific perspective in understanding cancer," says Murray Aitken, executive director of the IMS Institute, a global information and technology services company. "It's not a single disease but so many sub-diseases. ... We're at the edge of a major breakthrough in terms of cancer treatment. It's a very exciting time."
The report follows one from IMS Health released in April, which found that overall U.S. spending on drugs reached $373.9 billion in 2014 – a record high. This is largely attributable to the kinds of drugs on the market. Pharmaceutical companies are investing more and more in specialty medicines, such as complex, injected drugs rather than conventional treatments like pills. Spending on such specialty medicines grew 26.5 percent and accounted for one-third of medicine spending, up from 23 percent of the total spent five years ago. . . .
Spending for really excellent outcomes (significantly longer survivals -- or outright remissions) always makes sense, in my estimation. Onward -- it is an exciting time to be alive, indeed.
No comments:
Post a Comment